Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 601–700 of 1,000

Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer
Lee, S., & Seo, J. H. (2018) · BioMed Research International · doi:10.1155/2018/6074808 · Cited by 27
Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer
Chen, R., Guo, S., Yang, C., Sun, L., Zong, B., Li, K., Liu, L., Tu, G., Liu, M., & Liu, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4987 · Cited by 25
Bone-modifying Agents (BMAs) in Breast Cancer
Shapiro, C. L. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.04.009 · Cited by 26
Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer – A Review
Şerban, D., Costea, D. O., Zgura, A. F., Tudosie, M. S., Dascălu, A. M., Gangura, G. A., Smarandache, C. G., Sabău, A. D., Tudor, C., Faur, M., et al. (2021) · In Vivo · doi:10.21873/invivo.12674 · Cited by 25
Discovery of Thieno[2,3-e]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability
Lu, Z., Cao, Y., Zhang, D., Meng, X., Guo, B., Kong, D., & Yang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00008 · Cited by 25
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies
Lanza, O., Ferrera, A., Reale, S., Solfanelli, G., Petrungaro, M., Tini, G., Volpe, M., & Battistoni, A. (2022) · Medical Sciences · doi:10.3390/medsci10020027 · Cited by 26
Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update
Merlino, L., D’Ovidio, G., Matys, V., Piccioni, M. G., Porpora, M. G., Senatori, R., Viscardi, M. F., Vitale, A., & Rocca, C. D. (2023) · Pharmaceuticals · doi:10.3390/ph16040550 · Cited by 25
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
Tessari, A., Cosimo, S. D., & Palmieri, D. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53304 · Cited by 26
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
Lester, J., Dodwell, D. J., Brown, J. E., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., & Coleman, R. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.06.002 · Cited by 25
The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption
Swann, R., Perkins, K. A., Velentzis, L. S., Ciria, C., Dutton, S., Mulligan, A. A., Woodside, J. V., Cantwell, M. M., Leathem, A. J., Robertson, C. E., et al. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.03.018 · Cited by 27
Identifying patterns of breast cancer care provided at high-volume hospitals: a classification and regression tree analysis
Kong, A. L., Pezzin, L. E., & Nattinger, A. B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3561-6 · Cited by 25
The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring
Openshaw, M. R., Page, K., Fernández-García, D., Guttery, D. S., & Shaw, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1184974 · Cited by 27
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Maximov, P. Y., Abderrahman, B., Curpan, R. F., Hawsawi, Y. M., Fan, P., & Jordan, V. C. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0416 · Cited by 25
Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy
Brewster, A. M., Davies, K., & Cantor, S. B. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s52380 · Cited by 25
Emotional Freedom Techniques (EFT) to reduce the side effects associated with tamoxifen and aromatase inhibitor use in women with breast cancer: A service evaluation
Baker, B. S., & Hoffman, C. J. (2014) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2014.10.004 · Cited by 27
Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention
Dunn, B. K., & Ryan, A. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03688.x · Cited by 25
Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors
Yen, T. W. F., Czypinski, L. K., Sparapani, R., Guo, C., Laud, P. W., Pezzin, L. E., & Nattinger, A. B. (2010) · Cancer · doi:10.1002/cncr.25412 · Cited by 24
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 25
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus
Untch, M., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., Liedtke, C., Marschner, N. W., Möbus, V. J., Scheithauer, H., et al. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1546120 · Cited by 24
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Lerebours, F., Cabel, L., & Pierga, J. (2021) · Cancers · doi:10.3390/cancers13040902 · Cited by 26
Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective
Younus, M., Kissner, M., Reich, L., & Wallis, N. (2011) · Drug Safety · doi:10.2165/11594170-000000000-00000 · Cited by 24
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability
Dixon, J. M., Renshaw, L., Langridge, C., Young, O., McHugh, M., Williams, L. J., Murray, J., Macaskill, E. J., McCaig, F., Dixon, O. M., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1091-9 · Cited by 24
A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens
Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L. N. W., Wang, A., Eisenberg, M. T., Rowland, C. M., Hessling, J. J., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080070 · Cited by 24
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts
de Crémoux, P., Dalvai, M., N’Doye, O., Moutahir, F., Rolland, G., Chouchane-Mlik, O., Assayag, F., Lehmann‐Che, J., Kraus‐Berthier, L., Nicolas, A., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3233-y · Cited by 24
Overview of adjuvant trials of aromatase inhibitors in early breast cancer
Ingle, J. N. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.021 · Cited by 24
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial
Loehberg, C. R., Jud, S. M., Haeberle, L., Heusinger, K., Dilbat, G., Hein, A., Rauh, C., Dall, P., Rix, N., Heinrich, S., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0845-8 · Cited by 24
Committee Opinion No. 663
(2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001484 · Cited by 24
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance
Lobo-Martins, S., Arecco, L., Pina-Cabral, T., Agostinetto, E., Dauccia, C., Franzoi, M. A., Mastro, L. D., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105057 · Cited by 26
Analysis of Ki‐67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer
Iwata, H., Masuda, N., Sagara, Y., Kinoshita, T., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., et al. (2012) · Cancer · doi:10.1002/cncr.27818 · Cited by 23
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
Iwase, T., Saji, S., Iijima, K., Higaki, K., Ohtani, S., Sato, Y., Hozumi, Y., Hasegawa, Y., Yanagita, Y., Takei, H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00577 · Cited by 23
Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases
Dillekås, H., Transeth, M., Pilskog, M., Aßmus, J., & Straume, O. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3057-9 · Cited by 23
Prevention of osteoporosis after breast cancer
Reid, D. M. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.07.008 · Cited by 23
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs
Ataseven, B., Gunesch, A., EIERMANN, W., Kates, R. E., Hoegel, B., Knyazev, P. G., Ullrich, A., & Harbeck, N. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s62676 · Cited by 23
Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors
Olufade, T. O., Gallicchio, L. M., MacDonald, R., & Helzlsouer, K. J. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2364-3 · Cited by 23
A multidisciplinary team approach minimises prophylactic mastectomy rates
Leff, D. R., Ho, C., Thomas, H., Daniëls, R., Side, L. E., Lambert, F., Knight, J. A., Griffiths, M., Banwell, M., Aitken, J., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.02.017 · Cited by 23
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM
Hadji, P., Kieback, D., Tams, J., Hasenburg, A., & Ziller, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds055 · Cited by 23
Screening for osteoporosis after breast cancer: For whom, why and when
Trémollières, F. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.08.001 · Cited by 23
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Santa-Maria, C. A., Blackford, A. L., Nguyen, A., Skaar, T. C., Philips, S., Oesterreich, S., Rae, J. M., Desta, Z., Robarge, J., Henry, N. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1213 · Cited by 21
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
Sini, V., Cinieri, S., Conte, P., Laurentiis, M. D., Leo, A. D., Tondini, C. A., & Marchetti, P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.008 · Cited by 24
Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications
Mullooly, M., Pfeiffer, R. M., Nyante, S. J., Heckman‐Stoddard, B. M., Perloff, M., Jatoi, I., Brinton, L. A., Bowles, E. J. A., Hoover, R. N., Glass, A. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.4492 · Cited by 23
Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer
Higuchi, T., Endo, M., Hanamura, T., Gohno, T., Niwa, T., Yamaguchi, Y., Horiguchi, J., & Hayashi, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155844 · Cited by 23
Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial
Kyvernitakis, I., Kann, P. H., Thomasius, F. E., Hars, O., & Hadji, P. (2018) · Bone · doi:10.1016/j.bone.2018.06.007 · Cited by 23
Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study
Joseph, K. J., Zebak, S., Alba, V., Mah, K., Au, C., Vos, L. J., Ghosh, S., Abraham, A., Chafe, S., Wiebe, E. M., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.09.017 · Cited by 23
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
Gonnelli, S. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s3466 · Cited by 23
Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women With Breast Cancer Receiving Aromatase Inhibitors
Swenson, K. K., Nissen, M. J., Henly, S. J., Maybon, L., Pupkes, J., Zwicky, K., Tsai, M. L., & Shapiro, A. C. (2013) · Oncology nursing forum · doi:10.1188/13.onf.549-557 · Cited by 22
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial
Zdenkowski, N., Forbes, J., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C. M., Della‐Fiorentina, S. A., Kling, N., Campbell, I. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw055 · Cited by 23
Self-citation
Contralateral Prophylactic Mastectomy: What Do We Know and What Do Our Patients Know?
Khan, S. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4482 · Cited by 23
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
Mukherjee, A., & Davis, S. R. (2025) · Clinical Endocrinology · doi:10.1111/cen.15211 · Cited by 31
Breast cancer and osteoporosis
Cheung, A. M., Heisey, R., & Srighanthan, J. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000436195.10599.dd · Cited by 22
FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation
Yan, C., Gao, R., Gao, C., Hong, K., Cheng, M., Liu, X., Zhang, Q. H., & Zhang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1105117 · Cited by 22
Hormonal Therapy in Oncology: A Primer for the Radiologist
Fairchild, A., Tirumani, S. H., Rosenthal, M. H., Howard, S. A. H., Krajewski, K. M., Nishino, M., Shinagare, A. B., Jagannathan, J. P., & Ramaiya, N. H. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13604 · Cited by 22
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole
Menada, M. V., Costantini, S., Moioli, M., Bogliolo, S., Papadia, A., Ferrero, S., & Dugnani, M. C. (2008) · The Breast · doi:10.1016/j.breast.2008.05.008 · Cited by 22
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000
Shigematsu, H., Kawaguchi, H., Nakamura, Y., Tanaka, K., Shiotani, S., Koga, C., Nishimura, S., Taguchi, K., Nishiyama, K., & Ohno, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-118 · Cited by 22
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study
Yavaş, G., Yavaş, Ç., Acar, H., Toy, H., Yüce, D., & Ata, Ö. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1584-7 · Cited by 22
Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies
Basu, N., Barr, L. C., Ross, G. L., & Evans, D. G. (2015) · International Journal of Surgical Oncology · doi:10.1155/2015/901046 · Cited by 22
Breast cancer molecular subtypes – Modern therapeutic concepts for targeted therapy of a heterogeneous entity
Liedtke, C., & Kiesel, L. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.08.006 · Cited by 22
Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer
Tan, X., Camacho, F., Marshall, V. D., Donohoe, J., Anderson, R. T., & Balkrishnan, R. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.08.004 · Cited by 22
Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes
Hwang, G. S., Bhat, R. R., Crutchley, R. D., & Trivedi, M. V. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.36 · Cited by 22
The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer
Chin, A. L.-C., Bentley, J., & Pollom, E. L. (2018) · Cancer · doi:10.1002/cncr.31910 · Cited by 23
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial
Duffy, S., Distler, W., Howell, A., Cuzick, J. M., & Baum, M. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.07.062 · Cited by 22
Self-citation
Health State Utility Assessment for Breast Cancer
Shih, V., Chan, A., Xie, F., & Ko, Y. (2012) · Value in Health Regional Issues · doi:10.1016/j.vhri.2012.03.009 · Cited by 22
Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia
Bonanni, B., Serrano, D., Gandini, S., Guerrieri‐Gonzaga, A., Johansson, H. A., Macis, D., Cazzaniga, M., Luini, A., Cassano, E., Oldani, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1354 · Cited by 22
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
Saladores, P. H., Precht, J. C., Schroth, W., Brauch, H. B., & Schwab, M. G. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.26 · Cited by 22
Current and future approach to the pathologist’s assessment for targeted therapy in breast cancer
Pakkiri, P., Lakhani, S. R., & Smart, C. E. (2008) · Pathology · doi:10.1080/00313020802563551 · Cited by 22
The integrative bioinformatics approaches to predict the xanthohumol as anti-breast cancer molecule: Targeting cancer cells signaling PI3K and AKT kinase pathway
Gupta, K. K., Sharma, K. K., Chandra, H., Panwar, H., Bhardwaj, N., Altwaijry, N., Alsfouk, A. A., Dlamini, Z., Afzal, O., Altamimi, A. S. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950835 · Cited by 20
The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know
Hong, S., Didwania, A. D., Olopade, O. I., & Ganschow, P. S. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1037-2 · Cited by 21
IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer
Lakhanpal, R., Šestak, I., Shadbolt, B., Bennett, G., Brown, M. T., Phillips, T., Zhang, Y., Bullman, A., & Rezo, A. (2016) · The Breast · doi:10.1016/j.breast.2016.06.019 · Cited by 21
RET in breast cancer: pathogenic implications and mechanisms of drug resistance
Nigro, C. L., Rusmini, M., & Ceccherini, I. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.66 · Cited by 21
Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value
Wang, C., Chen, C., Lin, Y., Zhou, Y., Mao, F., Zhu, H., Zhang, X., Shen, S., Huang, X., Wang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61648-1 · Cited by 21
Influence of Traditional Chinese Medicine on Medical Adherence and Outcome in Estrogen Receptor (+) Breast Cancer Patients in Taiwan: A Real-World Population-Based Cohort Study
Chan, P.-W., Chiu, J., Huang, N., Chen, C., Yu, H., Liu, C., & Hsu, C.-H. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153365 · Cited by 21
Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials
Xie, M., Zhong, Y., Yang, Y., Shen, F., & Yue, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039320 · Cited by 21
Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer
Lee, S. J., Kim, K. M., Brown, J. K., Brett, A., Roh, Y. H., Kang, D. R., Park, B., & Rhee, Y. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0046-x · Cited by 21
Accelerated partial breast irradiation: Past, present, and future
Tann, A. W., Hatch, S. S., Joyner, M. M., Wiederhold, L. R., & Swanson, T. A. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.370 · Cited by 21
Primary antiphospholipid syndrome during aromatase inhibitors therapy
Tenti, S., Giordano, N. G., Cutolo, M., Giannini, F., & Fioravanti, A. (2019) · Medicine · doi:10.1097/md.0000000000015052 · Cited by 21
The function of uterine UDP-glucuronosyltransferase 1A8 (UGT1A8) and UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in endometrial cancer based on estrogen metabolism regulation
Zhao, F., Wang, X., Wang, Y., Zhang, J., Lai, R., Zhang, B., & Zhou, X. (2020) · HORMONES · doi:10.1007/s42000-020-00213-x · Cited by 21
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer
Traphagen, N. A., Hosford, S. R., Jiang, A., Marotti, J. D., Brauer, B. L., Demidenko, E., & Miller, T. W. (2021) · Oncogene · doi:10.1038/s41388-021-01782-w · Cited by 21
New views on treatment of aromatase inhibitors induced arthralgia
Xepapadakis, G., Ntasiou, P., Koronarchis, D., Koufoudakis, D., Panousis, D., Grosomanidis, D., Venizelos, V., & Georgiadis, S. (2010) · The Breast · doi:10.1016/j.breast.2010.03.031 · Cited by 21
Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?
Russell, N. S., Kunkler, I. H., van Tienhoven, G., Canney, P. A., Thomas, J. S. J., Bartlett, J. M. S., van de Vijver, M. J., Belkacémi, Y., Yarnold, J. R., & Barrett-Lee, P. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7062 · Cited by 21
Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis
Jeon, Y. W., You, S. H., Lee, J. E., Youn, H. J., Lim, W., Han, J. H., Park, C. H., & Kim, Y. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05426-2 · Cited by 20
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Buus, R., Szíjgyártó, Z., Schuster, E. F., Xiao, H. F., Haynes, B. P., Šestak, I., Cuzick, J. M., Paré, L., Seguí, E., Chic, N., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00216-w · Cited by 22
Self-citation
A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer
Harbeck, N., Burstein, H. J., Hurvitz, S. A., Johnston, S. R. D., & Vidal, G. A. (2022) · Cancer · doi:10.1002/cncr.34161 · Cited by 22
Breast cancer
Satherley, L. K., & Davies, E. L. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.008 · Cited by 20
Clinical utility of exemestane in the treatment of breast cancer
Montemurro, F., Zucchini, G., Geuna, E., Milani, A., Aversa, C., & Martinello, R. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s69475 · Cited by 21
Factors associated with contralateral preventive mastectomy
Yakoub, D., Avisar, E., Koru‐Sengul, T., Miao, F., Tannenbaum, S. L., Byrne, M. M., Moffat, F. L., Livingstone, A., & Franceschi, D. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s72737 · Cited by 20
Prioritizing Pharmacogenetic Research: A Value of Information Analysis of CYP2D6 Testing to Guide Breast Cancer Treatment
Woods, B. S., Veenstra, D. L., & Hawkins, N. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.048 · Cited by 20
Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes
Frederix, G., Severens, J. L., Hövels, A. M., Raaijmakers, J. A. M., & Schellens, J. H. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.08.003 · Cited by 20
Adjuvant therapy use among Appalachian breast cancer survivors
Tan, X., Marshall, V. D., Anderson, R. T., Donohoe, J., Camacho, F., & Balkrishnan, R. (2015) · Medicine · doi:10.1097/md.0000000000001071 · Cited by 20
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review
Jinih, M., Relihan, N., Corrigan, M. A., O’Reilly, S., & Redmond, H. P. (2017) · The Breast Journal · doi:10.1111/tbj.12783 · Cited by 20
Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
Hong, D., Bi, L., Zhou, J., Tong, Y., Zhao, Q. D., Chen, J., & Lu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17194 · Cited by 20
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review
Barros-Oliveira, M. D. C., Costa-Silva, D. R., de Andrade, D. B., Borges, U. S., Tavares, C. B., Borges, R. S., Silva, J. D. M., & da Silva, B. B. (2017) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.63.04.371 · Cited by 21
Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women
Kuba, S., Maeda, S., Matsumoto, M., Yamanouchi, K., Yano, H., Morita, M., Sakimura, C., Hatachi, T., Tokai, Y., Takatsuki, M., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.003 · Cited by 21
Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
Wickberg, Å., Liljegren, G., Killander, F., Lindman, H., Bjöhle, J., Carlberg, M., BLOMQVIST, C. P., Ahlgren, J., & Villman, K. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.04.002 · Cited by 20
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
Ross, D. S., Zehir, A., Brogi, E., Konno, F., Krystel‐Whittemore, M., Edelweiss, M., Berger, M. F., Toy, W., Chandarlapaty, S., Razavi, P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0116-5 · Cited by 22
Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia
Choo, S. B., Saifulbahri, A., Zullkifli, S. N., Fadzil, M. L., Redzuan, A. M., Abdullah, N., Bustamam, R. S., Ahmad, H., & Shah, N. M. (2018) · Climacteric · doi:10.1080/13697137.2018.1540563 · Cited by 20
Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity
Hu, Z., Li, Y., Xie, B., Ning, W., Yuan, X., Huang, Y., Zhao, C., Huang, J., Dong, C., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111605 · Cited by 20
Endocrine prevention of breast cancer
Jahan, N., Jones, C., & Rahman, R. L. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111284 · Cited by 19
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial
Tsai, C.-L., Liu, L., Liao, C.-Y., Liao, W., Liu, Y.-H., & Hsieh, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94466-0 · Cited by 23
Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis
Orlando, F. A., & Brown, K. D. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0500-y · Cited by 21
Clinical Presentation and Surgical Management of Invasive Lobular Carcinoma of the Breast
Dedes, K. J., & Fink, D. A. (2009) · Breast Disease · doi:10.3233/bd-2009-0277 · Cited by 20
Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales
Reyes‐García, R., Gimeno, E. J., Martín, A. G., Muñoz, M. R., Sáez, J. M. G., Fernández, I. L., Varsavsky, M., Iglesias, S. G., Rodríguez, I. C., Ballesteros-Pomar, M. D., et al. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.01.002 · Cited by 19

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks